Newswise — FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has published its 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC). One of the eight original NCCN Guidelines®, the NCCN Guidelines for SCLC was initially published in November 1996.
“There have indeed been major improvements in the NCCN process since 1996,” said Greg Kalemkerian, MD, Professor, Medical Oncology, University of Michigan Comprehensive Cancer Center, and NCCN Guidelines Panel Chair for SCLC. “Such improvements include the integration of a broader discipline representation on the NCCN Guidelines Panels, the availability of more evidence-based studies to support recommendations and choices, and the inclusion of the ‘Principles of’ sections that provide more detailed information of rationale and details of therapeutic regimens.”
Dr. Kalemkerian noted improvements in the treatment of SCLC since 1996, highlighting NCCN Guidelines recommendations such as the demonstration of survival benefit for prophylactic cranial radiation (PCI), raising PCI—a highly controversial procedure—from category 3 in 1996 to its current status as a category 1 recommendation, based on high-quality evidence and uniform consensus. Similarly, the demonstration of a survival benefit for second-line chemotherapy in relapsed SCLC, raised subsequent chemotherapy from a category 3 in 1996 to a category 1 recommendation today. Another improvement included the demonstration of a survival benefit for hyperfractioned thoracic radiotherapy in limited-stage SCLC.
Today, NCCN develops and publishes a library of 59 NCCN Guidelines, covering 97% of cancers affecting people in the United States. The NCCN Guidelines are developed and updated through an evidence-based process in which the expert panels integrate comprehensive clinical and scientific data with the judgment of the multidisciplinary panel members and other experts drawn from NCCN Member Institutions. Access to the complete library of NCCN Guidelines is available free-of-charge to clinicians at NCCN.org.
On March 12 – 14, 2015, the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ will be held at The Diplomat in Hollywood, Florida. In recognition of NCCN’s 20th Anniversary, NCCN is planning to hold a special live roundtable during the NCCN Annual Conference comprised of NCCN leadership – past and present— as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years; noteworthy historical NCCN accomplishments and events will be discussed, as well as the impact NCCN has had and continues to have on the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
To learn more about NCCN, the NCCN Guidelines, and the NCCN 20th Annual Conference, visit NCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer Center at The Nebraska Medical Center, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.